The US is Australia’s biggest export market for pharmaceuticals. If the tariffs go ahead, manufacturing could suffer.

Cancer survivors who received high-cost immunotherapies appear more likely to experience financial hardship, according to ...

There's little point in pouring hundreds of millions of dollars into creating a biosimilar if PBMs will refuse to cover it.